AANP PMHNP - PSYCHOPHARMACOLOGY AND MEDICATION
MANAGEMENT EXAM 400+ QUESTIONS AND ANSWERS WITH
RATIONALES 2026/2027 LATEST UPDATE
QUESTIONS 1–50: Pharmacology Foundations
1. Which pharmacokinetic process describes movement of a drug
from the GI tract into systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: B. Absorption is movement from the administration site into
systemic circulation.
2. Which organ is primarily responsible for hepatic first-pass
metabolism?
A. Kidney
B. Liver
C. Lung
D. Spleen
Answer: B. Drugs absorbed from the GI tract commonly pass through
the liver before reaching systemic circulation.
3. A drug's half-life refers to the time required for its plasma
concentration to:
A. Reach peak level
B. Fall by 25%
C. Fall by 50%
D. Become undetectable
Answer: C. Half-life is the time required for serum concentration to
decrease by approximately 50%.
,4. Approximately how long does it generally take to reach steady
state with repeated dosing?
A. One half-life
B. Two half-lives
C. Four to five half-lives
D. Ten half-lives
Answer: C. Most drugs approach steady state after approximately 4–5
half-lives.
5. A drug with a narrow therapeutic index requires:
A. No laboratory monitoring
B. Therapeutic drug monitoring when appropriate
C. Automatic dose doubling
D. Only symptom monitoring
Answer: B. Small differences between therapeutic and toxic
concentrations increase the importance of monitoring.
6. Pharmacodynamics primarily describes:
A. What the body does to the drug
B. What the drug does to the body
C. Drug elimination
D. Drug absorption
Answer: B. Pharmacodynamics concerns drug effects, receptor
interactions, and dose-response relationships.
7. Pharmacokinetics primarily describes:
A. Receptor activation
B. What the body does to a drug
C. Psychological effects
D. Therapeutic alliance
Answer: B. Pharmacokinetics includes absorption, distribution,
metabolism, and excretion.
,8. A competitive antagonist generally:
A. Activates the receptor
B. Permanently destroys the receptor
C. Competes with an agonist at the receptor
D. Increases agonist binding
Answer: C. Competitive antagonists compete for receptor occupancy
and can often be overcome by increasing agonist concentration.
9. An inverse agonist produces:
A. The opposite effect of constitutive receptor activity
B. No receptor effect
C. Only placebo effects
D. Irreversible receptor destruction
Answer: A. An inverse agonist decreases constitutive receptor activity.
10. Which patient characteristic generally increases risk for adverse
drug accumulation?
A. Increased renal clearance
B. Renal impairment
C. Younger age alone
D. Increased hepatic metabolism
Answer: B. Reduced renal clearance can increase serum concentrations
of renally eliminated medications.
11. Protein binding is clinically important because highly protein-
bound drugs may:
A. Never cross membranes
B. Have increased free-drug concentrations when binding decreases
C. Always have zero interactions
D. Never reach the CNS
Answer: B. Only unbound drug is generally pharmacologically available.
, 12. Which medication property favors CNS penetration?
A. High lipid solubility
B. Complete ionization
C. Very large molecular size
D. Exclusive protein binding
Answer: A. Lipid-soluble drugs generally cross the blood-brain barrier
more readily.
13. A CYP450 inhibitor generally causes the concentration of a
substrate drug to:
A. Decrease
B. Increase
C. Become zero
D. Remain predictably unchanged
Answer: B. Enzyme inhibition can reduce metabolism and increase
substrate exposure.
14. A CYP450 inducer generally causes substrate concentrations to:
A. Increase
B. Decrease
C. Become therapeutic automatically
D. Remain unchanged
Answer: B. Enzyme induction accelerates metabolism of susceptible
substrates.
15. Which is most likely to increase drug toxicity in an older adult?
A. Polypharmacy
B. Increased total body water
C. Increased renal function
D. Increased hepatic mass
Answer: A. Polypharmacy and age-related pharmacokinetic changes
increase adverse-event risk.
MANAGEMENT EXAM 400+ QUESTIONS AND ANSWERS WITH
RATIONALES 2026/2027 LATEST UPDATE
QUESTIONS 1–50: Pharmacology Foundations
1. Which pharmacokinetic process describes movement of a drug
from the GI tract into systemic circulation?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: B. Absorption is movement from the administration site into
systemic circulation.
2. Which organ is primarily responsible for hepatic first-pass
metabolism?
A. Kidney
B. Liver
C. Lung
D. Spleen
Answer: B. Drugs absorbed from the GI tract commonly pass through
the liver before reaching systemic circulation.
3. A drug's half-life refers to the time required for its plasma
concentration to:
A. Reach peak level
B. Fall by 25%
C. Fall by 50%
D. Become undetectable
Answer: C. Half-life is the time required for serum concentration to
decrease by approximately 50%.
,4. Approximately how long does it generally take to reach steady
state with repeated dosing?
A. One half-life
B. Two half-lives
C. Four to five half-lives
D. Ten half-lives
Answer: C. Most drugs approach steady state after approximately 4–5
half-lives.
5. A drug with a narrow therapeutic index requires:
A. No laboratory monitoring
B. Therapeutic drug monitoring when appropriate
C. Automatic dose doubling
D. Only symptom monitoring
Answer: B. Small differences between therapeutic and toxic
concentrations increase the importance of monitoring.
6. Pharmacodynamics primarily describes:
A. What the body does to the drug
B. What the drug does to the body
C. Drug elimination
D. Drug absorption
Answer: B. Pharmacodynamics concerns drug effects, receptor
interactions, and dose-response relationships.
7. Pharmacokinetics primarily describes:
A. Receptor activation
B. What the body does to a drug
C. Psychological effects
D. Therapeutic alliance
Answer: B. Pharmacokinetics includes absorption, distribution,
metabolism, and excretion.
,8. A competitive antagonist generally:
A. Activates the receptor
B. Permanently destroys the receptor
C. Competes with an agonist at the receptor
D. Increases agonist binding
Answer: C. Competitive antagonists compete for receptor occupancy
and can often be overcome by increasing agonist concentration.
9. An inverse agonist produces:
A. The opposite effect of constitutive receptor activity
B. No receptor effect
C. Only placebo effects
D. Irreversible receptor destruction
Answer: A. An inverse agonist decreases constitutive receptor activity.
10. Which patient characteristic generally increases risk for adverse
drug accumulation?
A. Increased renal clearance
B. Renal impairment
C. Younger age alone
D. Increased hepatic metabolism
Answer: B. Reduced renal clearance can increase serum concentrations
of renally eliminated medications.
11. Protein binding is clinically important because highly protein-
bound drugs may:
A. Never cross membranes
B. Have increased free-drug concentrations when binding decreases
C. Always have zero interactions
D. Never reach the CNS
Answer: B. Only unbound drug is generally pharmacologically available.
, 12. Which medication property favors CNS penetration?
A. High lipid solubility
B. Complete ionization
C. Very large molecular size
D. Exclusive protein binding
Answer: A. Lipid-soluble drugs generally cross the blood-brain barrier
more readily.
13. A CYP450 inhibitor generally causes the concentration of a
substrate drug to:
A. Decrease
B. Increase
C. Become zero
D. Remain predictably unchanged
Answer: B. Enzyme inhibition can reduce metabolism and increase
substrate exposure.
14. A CYP450 inducer generally causes substrate concentrations to:
A. Increase
B. Decrease
C. Become therapeutic automatically
D. Remain unchanged
Answer: B. Enzyme induction accelerates metabolism of susceptible
substrates.
15. Which is most likely to increase drug toxicity in an older adult?
A. Polypharmacy
B. Increased total body water
C. Increased renal function
D. Increased hepatic mass
Answer: A. Polypharmacy and age-related pharmacokinetic changes
increase adverse-event risk.
